Skip to content
Search

Latest Stories

US Senate approves technology bill to counter China

US Senate approves technology bill to counter China

THE US SENATE has approved a huge spending plan of approximately £176 billion to boost technology research and production in the country.

Republicans and Democrats came together to pass the bill that came in the wake of growing international competition, particularly from China.


The bill must pass the House of Representatives before it is signed into law.

"I believe that this legislation will enable the United States to out-innovate, out-produce, and out-compete the world in the industries of the future," Senate majority leader and co-sponsor of the bill Chuck Schumer said.

The proposed amount will be used for technology research, semiconductor development and manufacturing along with subsidies for robot makers and chipmakers amid a dearth of computer chips worldwide.

A shortage of computer chips has affected automobile production at a time when global demand is rebounding.

The bill also includes a number of China-specific provisions, including the prohibition of the social media app TikTok from being downloaded on government devices.

It also prohibits the purchase of drones manufactured and sold by Chinese state enterprises.

Further, Chinese organisations engaged in US cyber attacks or intellectual property theft from US firms would face sanctions.

The bill indicates some signs of a thaw in relations between Beijing and Washington.

US president Joe Biden praised the bill's passage.

"It is long past time that we invest in American workers and American innovation," Biden said in a statement.

"We are in a competition to win the 21st century, and the starting gun has gone off. As other countries continue to invest in their own research and development, we cannot risk falling behind," he added.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less